Dedicated to Improving the Lives of Patients with Food Allergies and Other Immunological Diseases

Merging Science and Technology for Differentiated Drug Development

Focused on Advancing Transformative Treatments to Help Patients and their Caregivers

Our Journey

DBV Technologies is a global clinical stage biopharmaceutical company founded by pediatricians and entrepreneurs who believed that food allergies could one day be treated safely and effectively. With this mission driving our commitment to the advancement of treatments in this field, we are investigating a potential new class of immunotherapy that aims to activate the immune system of patients through the skin.

Read More

For more than 15 years, we have been on a journey to advance skin immunotherapy, which merges deep science with patented manufacturing technologies and proprietary manufacturing to develop treatment options for diseases with significant unmet medical need.

Today, we are focused on exploring the use of skin immunotherapy to address food allergies, a devastating condition that afflicts millions of patients. As an important milestone in our journey of developing medicines, we hope to potentially offer the first FDA approved epicutaneous immunotherapy (EPIT®) treatment for peanut allergy.

Tomorrow, as pioneers, we plan to explore the boundaries of this potential new class of immunotherapy to develop transformative treatments for patients suffering from other conditions, including inflammatory and autoimmune diseases.

Patients:
At the Core of Everything We Do

Food allergies are serious medical conditions that occur when the body has a specific immune response to certain foods. In people with food allergies, the immune system mistakenly responds to a certain food as if it were harmful. The body’s immune response can be potentially life-threatening, such as anaphylaxis, which is a sudden and severe allergic reaction that may cause death.

Read More

The symptoms and severity of allergic reactions to food can be different between individuals and can also range in severity for the same person.

Currently, there is no cure for food allergies. Strict avoidance of offending allergens and management of allergic reactions are the only measures that can help prevent serious health consequences for these patients.

For several decades, food-allergic patients have seen limited pharmaceutical development in this field, and today have no approved treatments available. At DBV, we are committed to investigating and developing potential treatments for food allergies. For more than a decade, our teams of top scientists and clinicians have been leading the development and patenting of a technology platform called Viaskin®.

The Viaskin® Platform

Investigating a Potential New Class of Immunotherapy through Our Proprietary Technology Platform, Viaskin

As a potential new class of treatment, Viaskin is designed to activate the immune system through the skin, which may offer a self-administered and non-invasive treatment option to patients.

picture1
This is for illustration purposes only. This potential patch and epicutaneous immunotherapy are under clinical investigation and have not been approved for use or marketing in the United States or any other country.

Investigational Epicutaneous Immunotherapy (EPIT)

DBV Aims to Unlock the Powerful Immune Properties of the Skin

Our investigational, proprietary treatment is based on EPIT. This potential new class of immunotherapy is designed to work by delivering allergens to the immune system through intact skin using our proprietary Viaskin platform.

For patients facing life-threatening food allergies, this investigational immunotherapy treatment aims to desensitize them to allergens by delivering compounds in small quantities into the outer layers of the skin.

Promise and Hope for the Future: Finding Potential Treatment Options

We are developing the Viaskin technology platform to help improve the lives of patients suffering from peanut and other food allergies. Programs in development include late stage clinical trials of Viaskin Peanut and Viaskin Milk, as well as pre-clinical studies of Viaskin Egg.

peanut

VIASKIN® PEANUT

milk

VIASKIN® MILK

eggs

VIASKIN® EGG

pierre henri benhamou pdg DBV

“The ultimate goal is to change the life of the food-allergic patient …We have these patients’ lives in mind with every bit of progress that we make toward the development of Viaskin.”

Dr. Pierre-Henri Benhamou
Co-founder

Our Pipeline

Ongoing Clinical Trials

DBV’s robust development program includes ongoing clinical trials of Viaskin Peanut and Viaskin Milk and pre-clinical development of Viaskin Egg.

Viaskin’s potential to unlock the immune properties of skin makes it a promising therapeutic approach beyond food allergies. DBV is investigating other areas of significant unmet medical need, including Eosinophilic Esophagitis (EoE), vaccines, inflammatory conditions and autoimmune diseases.

Latest News

DocumentYearTerms

10/10/2019 - 7:30 am

DBV Technologies Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares in Connection With its Global Offering of Ordinary Shares in the Form of American Depositary Shares (ADSs)

Download PDF (219 KB)

10/09/2019 - 7:30 am

DBV Technologies Announces Pricing of $125 million (€114 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares

Download PDF (190 KB)

10/08/2019 - 10:15 pm | Corporate

DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares, and Reports September 30, 2019 Cash Position

Download PDF (182 KB)